Catherine Hayward

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3756807/publications.pdf

Version: 2024-02-01

143 papers	4,992 citations	94433 37 h-index	98798 67 g-index
144 all docs	144 docs citations	144 times ranked	2784 citing authors

#	Article	IF	Citations
1	Recommendations for the standardization of light transmission aggregometry: a consensus of the working party from the platelet physiology subcommittee of SSC/ISTH. Journal of Thrombosis and Haemostasis, 2013, 11, 1183-1189.	3.8	398
2	Platelet function analyzer (PFA)â€100Â® closure time in the evaluation of platelet disorders and platelet function. Journal of Thrombosis and Haemostasis, 2006, 4, 312-319.	3.8	382
3	Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and the relationship between platelet counts, endogenous thrombopoietin, and circulating antithrombopoietin antibodies. American Journal of Hematology, 2004, 76, 205-213.	4.1	197
4	Results of a worldwide survey on the assessment of platelet function by light transmission aggregometry: a report from the platelet physiology subcommittee of the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2009, 7, 1029.	3.8	177
5	Heparinâ€induced thrombocytopenia and thrombosis: clinical and laboratory studies. British Journal of Haematology, 1993, 84, 322-328.	2.5	175
6	Development of North American Consensus Guidelines for Medical Laboratories That Perform and Interpret Platelet Function Testing Using Light Transmission Aggregometry. American Journal of Clinical Pathology, 2010, 134, 955-963.	0.7	173
7	The epitope specificity of heparinâ€induced thrombocytopenia. British Journal of Haematology, 1996, 95, 161-167.	2.5	152
8	Diagnostic utility of light transmission platelet aggregometry: results from a prospective study of individuals referred for bleeding disorder assessments. Journal of Thrombosis and Haemostasis, 2009, 7, 676-684.	3.8	141
9	Congenital platelet disorders: overview of their mechanisms, diagnostic evaluation and treatment. Haemophilia, 2006, 12, 128-136.	2.1	138
10	A diagnostic test for heparinâ€induced thrombocytopenia: detection of platelet microparticles using flow cytometry. British Journal of Haematology, 1996, 95, 724-731.	2.5	125
11	Variability in clinical laboratory practice in testing for disorders of platelet function. Thrombosis and Haemostasis, 2005, 93, 549-553.	3.4	119
12	Platelets from patients with the Quebec platelet disorder contain and secrete abnormal amounts of urokinase-type plasminogen activator. Blood, 2001, 98, 257-265.	1.4	116
13	Bleeding risks associated with inheritance of the Quebec platelet disorder. Blood, 2004, 104, 159-165.	1.4	102
14	Persons with Quebec platelet disorder have a tandem duplication of PLAU, the urokinase plasminogen activator gene. Blood, 2010, 115, 1264-1266.	1.4	87
15	Diagnostic Usefulness of a Lumi-Aggregometer Adenosine Triphosphate Release Assay for the Assessment of Platelet Function Disorders. American Journal of Clinical Pathology, 2011, 136, 350-358.	0.7	70
16	Platelet Function Testing: Quality Assurance. Seminars in Thrombosis and Hemostasis, 2007, 33, 273-282.	2.7	64
17	Validation of the ISTH/SSC bleeding assessment tool for inherited platelet disorders: A communication from the Platelet Physiology SSC. Journal of Thrombosis and Haemostasis, 2020, 18, 732-739.	3.8	64
18	The cDNA Sequence of Human Endothelial Cell Multimerin. Journal of Biological Chemistry, 1995, 270, 18246-18251.	3.4	62

#	Article	IF	Citations
19	Studies of a Second Family With the Quebec Platelet Disorder: Evidence That the Degradation of the Î±-Granule Membrane and Its Soluble Contents Are Not Secondary to a Defect in Targeting Proteins to Î±-Granules. Blood, 1997, 89, 1243-1253.	1.4	61
20	Laboratory testing for heparin-induced thrombocytopenia is inconsistent in North America: A survey of North American specialized coagulation laboratories. Thrombosis and Haemostasis, 2007, 98, 1357-1361.	3.4	60
21	Quebec Platelet Disorder: Update on Pathogenesis, Diagnosis, and Treatment. Seminars in Thrombosis and Hemostasis, 2011, 37, 713-720.	2.7	58
22	An evaluation of methods for determining reference intervals for light transmission platelet aggregation tests on samples with normal or reduced platelet counts. Thrombosis and Haemostasis, 2008, 100, 134-45.	3.4	55
23	Factor V Is Complexed with Multimerin in Resting Platelet Lysates and Colocalizes with Multimerin in Platelet Î±-Granules. Journal of Biological Chemistry, 1995, 270, 19217-19224.	3.4	54
24	Diagnostic evaluation of platelet function disorders. Blood Reviews, 2011, 25, 169-173.	5.7	54
25	Results of an External Proficiency Testing Exercise on Platelet Dense-Granule Deficiency Testing by Whole Mount Electron Microscopy. American Journal of Clinical Pathology, 2009, 131, 671-675.	0.7	50
26	Mice with deleted multimerin 1 and Î±-synuclein genes have impaired platelet adhesion and impaired thrombus formation that is corrected by multimerin 1. Thrombosis Research, 2010, 125, e177-e183.	1.7	50
27	Quebec platelet disorder is linked to the urokinase plasminogen activator gene (PLAU) and increases expression of the linked allele in megakaryocytes. Blood, 2009, 113, 1543-1546.	1.4	49
28	Inherited disorders of platelet alpha-granules. Platelets, 1997, 8, 197-210.	2.3	47
29	Insights into abnormal hemostasis in the Quebec platelet disorder from analyses of clot lysis. Journal of Thrombosis and Haemostasis, 2006, 4, 1086-1094.	3.8	47
30	Quebec platelet disorder: features, pathogenesis and treatment. Blood Coagulation and Fibrinolysis, 2008, 19, 109-119.	1.0	46
31	Analyses of cellular multimerin 1 receptors: in vitro evidence of binding mediated by Î±Î™Î™bÎ²3 and Î±vÎ²3. Thrombosis and Haemostasis, 2005, 94, 1004-1011.	3.4	43
32	Electron microscopy examination of platelet whole mount preparations to quantitate platelet dense granule numbers: Implications for diagnosing suspected platelet function disorders due to dense granule deficiency. International Journal of Laboratory Hematology, 2018, 40, 400-407.	1.3	42
33	Laboratory Investigations for Bleeding Disorders. Seminars in Thrombosis and Hemostasis, 2012, 38, 742-752.	2.7	41
34	Prophylactic and perioperative replacement therapy for acquired factor XIII deficiency. Journal of Thrombosis and Haemostasis, 2004, 2, 1017-1019.	3.8	40
35	Diagnostic Assessment of Platelet Disorders: What Are the Challenges to Standardization?. Seminars in Thrombosis and Hemostasis, 2009, 35, 131-138.	2.7	40
36	Increased expression of urokinase plasminogen activator in Quebec platelet disorder is linked to megakaryocyte differentiation. Blood, 2009, 113, 1535-1542.	1.4	40

#	Article	IF	Citations
37	Laboratory testing for fibrinogen abnormalities. American Journal of Hematology, 2008, 83, 928-931.	4.1	39
38	Multimerin 1. Platelets, 2008, 19, 83-95.	2.3	39
39	A prospective cohort study of light transmission platelet aggregometry for bleeding disorders: Is testing native platelet-rich plasma non-inferior to testing platelet count adjusted samples?. Thrombosis and Haemostasis, 2011, 106, 675-682.	3.4	39
40	Intracellular activation of the fibrinolytic cascade in the Quebec Platelet Disorder. Thrombosis and Haemostasis, 2003, 90, 293-298.	3.4	37
41	Evaluation of an automated method for measuring von <scp>W</scp>illebrand factor activity in clinical samples without ristocetin. International Journal of Laboratory Hematology, 2014, 36, 341-351.	1.3	36
42	Are laboratories following published recommendations for lupus anticoagulant testing?. Thrombosis and Haemostasis, 2009, 101, 178-184.	3.4	35
43	How I investigate for bleeding disorders. International Journal of Laboratory Hematology, 2018, 40, 6-14.	1.3	35
44	Quebec platelet disorder. Expert Review of Hematology, 2011, 4, 137-141.	2.2	34
45	Diagnostic approach to platelet function disorders. Transfusion and Apheresis Science, 2008, 38, 65-76.	1.0	33
46	Multimerin 1 binds factor V and activated factor V with high affinity and inhibits thrombin generation. Thrombosis and Haemostasis, 2008, 100, 1058-1067.	3.4	33
47	External Quality Assessment of Platelet Disorder Investigations: Results of International Surveys on Diagnostic Tests for Dense Granule Deficiency and Platelet Aggregometry Interpretation. Seminars in Thrombosis and Hemostasis, 2012, 38, 622-631.	2.7	33
48	Approaches to investigating common bleeding disorders: An evaluation of North American coagulation laboratory practices. American Journal of Hematology, 2012, 87, S45-50.	4.1	33
49	Endocytosis and storage of plasma factor V by human megakaryocytes. Thrombosis and Haemostasis, 2005, 94, 585-592.	3.4	32
50	Studies of Multimerin in Human Endothelial Cells. Blood, 1998, 91, 1304-1317.	1.4	30
51	Diagnosis and Management of Mild Bleeding Disorders. Hematology American Society of Hematology Education Program, 2005, 2005, 423-428.	2.5	30
52	Platelet factor V New York: A defect in factor V distinct from that in factor V Quebec resulting in impaired prothrombinase generation. American Journal of Hematology, 2001, 66, 130-139.	4.1	29
53	Variability in platelet dense granule adenosine triphosphate release findings amongst patients tested multiple times as part of an assessment for a bleeding disorder. International Journal of Laboratory Hematology, 2016, 38, 648-657.	1.3	28
54	Genetic Loci Associated with Platelet Traits and Platelet Disorders. Seminars in Thrombosis and Hemostasis, 2013, 39, 291-305.	2.7	26

#	Article	IF	Citations
55	Laboratory testing for bleeding disorders: strategic uses of high and lowâ€yield tests. International Journal of Laboratory Hematology, 2013, 35, 322-333.	1.3	25
56	Inherited platelet disorders. Current Opinion in Hematology, 2003, 10, 362-368.	2.5	24
57	Critical Values in the Coagulation Laboratory. American Journal of Clinical Pathology, 2011, 136, 836-841.	0.7	24
58	Update on diagnostic testing for platelet function disorders: What is practical and useful?. International Journal of Laboratory Hematology, 2019, 41, 26-32.	1.3	24
59	The storage defects in grey platelet syndrome and Î±Î´-storage pool deficiency affect Î±-granule factor V and multimerin storage without altering their proteolytic processing. British Journal of Haematology, 2001, 113, 871-877.	2.5	23
60	Factor XIII Assays and Associated Problems for Laboratory Diagnosis of Factor XIII Deficiency: An Analysis of International Proficiency Testing Results. Seminars in Thrombosis and Hemostasis, 2014, 40, 232-238.	2.7	23
61	Fibrinogen degradation products in patients with the Quebec platelet disorder. British Journal of Haematology, 1997, 97, 497-503.	2.5	20
62	Human platelets contain forms of factor V in disulfide-linkage with multimerin. Thrombosis and Haemostasis, 2004, 92, 1349-1357.	3.4	20
63	An evaluation of methods for determining reference intervals for light transmission platelet aggregation tests on samples with normal or reduced platelet counts. Thrombosis and Haemostasis, 2008, 100, 01-12.	3.4	20
64	Platelet adhesion to multimerin 1 in vitro: influences of platelet membrane receptors, von Willebrand factor and shear. Journal of Thrombosis and Haemostasis, 2009, 7, 685-692.	3.8	20
65	Multimerin 1 binds factor V and activated factor V with high affinity and inhibits thrombin generation. Thrombosis and Haemostasis, 2008, 100, 1058-67.	3.4	20
66	Dissociation between the level of von Willebrand factor-cleaving protease activity and disease in a patient with congenital thrombotic thrombocytopenic purpura. American Journal of Hematology, 2004, 77, 387-390.	4.1	19
67	Simultaneous measurement of adenosine triphosphate release and aggregation potentiates human platelet aggregation responses for some subjects, including persons with Quebec platelet disorder. Thrombosis and Haemostasis, 2012, 107, 726-734.	3.4	19
68	The ISTH bleeding assessment tool as predictor of bleeding events in inherited platelet disorders: Communication from the ISTH SSC Subcommittee on Platelet Physiology. Journal of Thrombosis and Haemostasis, 2021, 19, 1364-1371.	3.8	19
69	Clinician Investigator Training in Canada: A Review. Clinical and Investigative Medicine, 2011, 34, 192.	0.6	19
70	Isolation and characterization of cysteine proteinase in thrombotic thrombocytopenic purpura. British Journal of Haematology, 1996, 93, 421-426.	2.5	18
71	Studies of Î±-granule proteins in cultured human megakaryocytes. Thrombosis and Haemostasis, 2003, 90, 844-852.	3.4	18
72	Protein C Assay Performance. American Journal of Clinical Pathology, 2012, 137, 909-915.	0.7	18

#	Article	IF	Citations
73	The duplication mutation of Quebec platelet disorder dysregulates PLAU, but not C10orf55, selectively increasing production of normal PLAU transcripts by megakaryocytes but not granulocytes. PLoS ONE, 2017, 12, e0173991.	2.5	18
74	The prenatal identification of fetal compatibility in neonatal alloimmune thrombocytopenia using amniotic fluid and variable number of tandem repeat (VNTR) analysis. British Journal of Haematology, 1995, 91, 742-746.	2.5	17
75	Identification of the MMRN1 Binding Region within the C2 Domain of Human Factor V. Journal of Biological Chemistry, 2004, 279, 51466-51471.	3.4	17
76	Multimerin Processing by Cells With and Without Pathways for Regulated Protein Secretion. Blood, 1999, 94, 1337-1347.	1.4	15
77	An Assessment of the State of Current Practice in Coagulation Laboratories. American Journal of Clinical Pathology, 2016, 146, 378-383.	0.7	15
78	Multimerin 1 supports platelet function in vivo and binds to specific GPAGPOGPX motifs in fibrillar collagens that enhance platelet adhesion. Journal of Thrombosis and Haemostasis, 2021, 19, 547-561.	3.8	15
79	Severe thrombophilia in a factor Vâ€deficient patient homozygous for the Ala2086Asp mutation (FV) Tj ETQq1 1 0.784314 rgBT /Ove	3.8	15
80	Molecular phenotype and bleeding risks of an inherited platelet disorder in a family with a <scp>RUNX</scp>1 frameshift mutation. Haemophilia, 2017, 23, e204-e213.	2.1	14
81	Diagnostic Evaluation of Platelet Disorders: The Past, the Present, and the Future. Seminars in Thrombosis and Hemostasis, 2009, 35, 127-130.	2.7	13
82	Enhancer-gene rewiring in the pathogenesis of Quebec Platelet Disorder. Blood, 2020, 136, 2679-2690.	1.4	13
83	Bleeding and thrombotic problems in a patient with alpha2 plasmin inhibitor deficiency. Journal of Thrombosis and Haemostasis, 2005, 3, 399-401.	3.8	12
84	Platelet function analyzer (PFA)-100Rclosure time in the evaluation of platelet disorders and platelet function: reply to a rebuttal. Journal of Thrombosis and Haemostasis, 2006, 4, 1433-1434.	3.8	12
85	Evaluation of urokinase plasminogen activator in urine from individuals with Quebec platelet disorder. Blood Coagulation and Fibrinolysis, 2008, 19, 463-464.	1.0	12
86	Technological advances in diagnostic testing for von Willebrand disease: new approaches and challenges. International Journal of Laboratory Hematology, 2014, 36, 334-340.	1.3	12
87	An acquired factor V inhibitor associated with defective factor V function, storage and binding to multimerin 1. Journal of Thrombosis and Haemostasis, 2008, 6, 395-397.	3.8	11
88	Multimerin. Current Opinion in Hematology, 1995, 2, 339-344.	2.5	9
89	Multimerin: A Multimeric Protein Stored in Platelet Alpha-granules. Platelets, 1995, 6, 1-10.	2.3	9
90	Platelet function analyzer (PFA)-100R closure time in the evaluation of platelet disorders and platelet function: reply to a rebuttal. Journal of Thrombosis and Haemostasis, 2006, 4, 1432-1432.	3.8	9

#	Article	IF	Citations
91	Assembly and evaluation of an inventory of guidelines that are available to support clinical hematology laboratory practice. International Journal of Laboratory Hematology, 2015, 37, 36-45.	1.3	9
92	The functions of the A1A2A3 domains in von Willebrand factor include multimerin 1 binding. Thrombosis and Haemostasis, 2016, 116, 87-95.	3.4	9
93	Analytical Performance of COVID-19 Detection Methods (RT-PCR): Scientific and Societal Concerns. Life, 2021, 11, 660.	2.4	9
94	An acquired factor V inhibitor associated with defective factor V function, storage and binding to multimerin 1. Journal of Thrombosis and Haemostasis, 2008, 6, 395-397.	3.8	9
95	Expert Approaches to Common Bleeding and Thrombotic Problemsâ€"Part I. Seminars in Thrombosis and Hemostasis, 2012, 38, 641-644.	2.7	8
96	Thrombin generation abnormalities in Quebec platelet disorder. International Journal of Laboratory Hematology, 2020, 42, 801-809.	1.3	8
97	Bleeding risks for uncharacterized platelet function disorders. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 799-806.	2.3	8
98	Screening and diagnosis of inherited platelet disorders. Critical Reviews in Clinical Laboratory Sciences, 2022, 59, 405-444.	6.1	8
99	Thrombin generation abnormalities in commonly encountered platelet function disorders. International Journal of Laboratory Hematology, 2021, 43, 1557-1565.	1.3	7
100	Studies of multimerin in patients with von Willebrand disease and platelet von Willebrand factor deficiency. British Journal of Haematology, 1998, 103, 20-28.	2.5	6
101	Report on the International Society for Laboratory Hematology Survey on guidelines to support clinical hematology laboratory practice. International Journal of Laboratory Hematology, 2016, 38, 133-138.	1.3	6
102	Bacterial infectionâ€associated improvement of platelet counts in two patients with chronic and unresponsive idiopathic thrombocytopenic purpura with normal platelet survival studies. British Journal of Haematology, 1995, 90, 332-335.	2.5	5
103	PROTEOLYTIC DEGRADATION OF HIGH MOLECULAR WEIGHT KININOGEN IN ACUTE THROMBOTIC THROMBOCYTOPENIC PURPURA. British Journal of Haematology, 1997, 97, 762-767.	2.5	5
104	Measurement of endogenous and exogenous alphaâ€granular platelet proteins in patients with immune and nonimmune thrombocytopenia. British Journal of Haematology, 1999, 106, 762-770.	2.5	5
105	Thrombocytopenic Platelet Disorders. Seminars in Thrombosis and Hemostasis, 2011, 37, 617-620.	2.7	5
106	Genomic approaches to bleeding disorders. Haemophilia, 2016, 22, 42-45.	2.1	5
107	Urokinase-Type Plasminogen Activator Production by Cultured Megakaryocytes and Blood Outgrowth Endothelial Cells in the Quebec Platelet Disorder.. Blood, 2006, 108, 1008-1008.	1.4	5
108	Platelet Multimerin and Its Proteolytic Processing. Thrombosis and Haemostasis, 1999, 82, 1779-1780.	3.4	4

#	Article	IF	Citations
109	Location of the multimerin 1 binding site in coagulation factor V: An update. Thrombosis Research, 2008, 123, 352-354.	1.7	4
110	Thrombopoietin levels in Quebec platelet disorderâ€"Implications for the mechanism of thrombocytopenia. International Journal of Laboratory Hematology, 2018, 40, e33-e34.	1.3	4
111	Laboratory issues in bleeding disorders. Haemophilia, 2008, 14, 93-103.	2.1	3
112	Platelet Aggregation. , 2013, , 559-580.		3
113	Improving blood disorder diagnosis: reflections on the challenges. International Journal of Laboratory Hematology, 2013, 35, 244-253.	1.3	3
114	Proteomics in the Study of Qualitative Platelet Defects: Validation of the Approach in the Gray Platelet Syndrome and Quebec Platelet Disorder.. Blood, 2007, 110, 3900-3900.	1.4	3
115	Prophylactic and perioperative replacement therapy for acquired factor XIII deficiency: reply to a rebuttal. Journal of Thrombosis and Haemostasis, 2005, 3, 187-188.	3.8	2
116	Advances in Understanding â€œHigh on-Treatment Platelet Reactivityâ€• Thrombosis and Haemostasis, 2009, 102, 799-800.	3.4	2
117	Clinical Approach to the Patient With Bleeding or Bruising. , 2018, , 1912-1921.		2
118	Platelet Aggregation. , 2019, , 609-626.		2
119	Improved platelet counts during prolonged tranexamic therapy for Quebec platelet disorder implicate the underlying fibrinolytic defect as the cause of lower platelet counts. International Journal of Laboratory Hematology, 2020, 42, e274-e276.	1.3	2
120	Gender Differences in Bleeding Problems and Implications for the Assessment of a Bleeding Disorder.. Blood, 2007, 110, 2148-2148.	1.4	2
121	Management of a Left Atrial Appendage Thrombus Due to Atrial Fibrillation Complicating QuÃ©bec Platelet Disorder. Canadian Journal of Cardiology, 2022, 38, 1464-1466.	1.7	2
122	Expert Approaches to Common Bleeding and Thrombotic Problems, Part II. Seminars in Thrombosis and Hemostasis, 2013, 39, 113-116.	2.7	1
123	Platelet Aggregation. , 2017, , 619-635.		1
124	Update on major activities of the International Society for Laboratory Hematology. International Journal of Laboratory Hematology, 2020, 42, 4-5.	1.3	1
125	Patient advocacy and its importance to laboratory medicine practice. International Journal of Laboratory Hematology, 2020, 42, 21-22.	1.3	1
126	Memorial notice: Elizabeth M. Van Cott MD. International Journal of Laboratory Hematology, 2021, 43, 530-531.	1.3	1

#	Article	IF	Citations
127	C57BL/6JOlaHsd Mice with Tandem Deletion of the Multimerin 1 and Alpha-Synuclein Genes Have Impaired Platelet Function in Vivo and in Vitro That Can Be Corrected by Multimerin 1. Blood, 2008, 112, 3926-3926.	1.4	1
128	New perspectives: the President's update on the International Society for Laboratory Hematology. International Journal of Laboratory Hematology, 2016, 38, 3-4.	1.3	0
129	Update from the President on the International Society for Laboratory Hematology, including initiatives to promote education and best practices. International Journal of Laboratory Hematology, 2017, 39, 4-5.	1.3	0
130	Update from the President of the International Society for Laboratory Hematology initiatives to promote education, mentorship, best practices, and collaboration. International Journal of Laboratory Hematology, 2018, 40, 4-5.	1.3	0
131	Update from the President of the International Society for Laboratory Hematology on major activities of our society. International Journal of Laboratory Hematology, 2019, 41, 6-7.	1.3	0
132	Unraveling von Willebrand factor deficiency. Blood, 2021, 137, 3160-3161.	1.4	0
133	Human Platelets Contain Forms of Factor V in Disulfide-Linkage with Multimerin.. Blood, 2004, 104, 1933-1933.	1.4	0
134	The Proadhesive Properties of Multimerin in Supporting Cellular Adhesion: Evidence for RGD and Non-RGD Dependent Adhesive Mechanisms.. Blood, 2004, 104, 3917-3917.	1.4	0
135	Identification of the Multimerin Binding Region within the C2 Domain of Human Factor V Using Constructs Generated by Alanine-Scanning and Site-Directed Mutagenesis.. Blood, 2004, 104, 124-124.	1.4	0
136	Insights into Disturbed Hemostasis in the Quebec Platelet Disorder Using Thromboelastography, Blood Clots Formed at Low Shear, and Perfusion Studies of Fibrinolysis.. Blood, 2005, 106, 2135-2135.	1.4	0
137	Pitfalls in Interpreting Platelet Function Tests in Thrombocytopenic Patients Referred by a Hematologist for Diagnostic Testing: Results from a Single Center Prospective Study.. Blood, 2005, 106, 3982-3982.	1.4	0
138	Phospholipid Components of the Activated Platelet Surface Determine Multimerin 1 and Factor V/Va Binding, and Modulate Thrombin Generation in Plasma.. Blood, 2006, 108, 3911-3911.	1.4	0
139	Factor V Binding to Multimerin 1: Modulation by Factor V Activation and Binding Sites in the Factor V C1 and C2 Domains.. Blood, 2006, 108, 193-193.	1.4	0
140	Effects of Multimerin 1 on Platelet and Plasma FV as Determined by Calibrated Automated Thrombography.. Blood, 2006, 108, 1607-1607.	1.4	0
141	Phospholipid composition influences the binding of multimerin 1 and factor V/Va to the platelet membrane and modulates thrombin generation in plasma. FASEB Journal, 2007, 21, A980.	0.5	0
142	Dysregulation of C10orf55 Expression in Megakaryocytic Cell Lineage From Quebec Platelet Disorder Individuals. Blood, 2011, 118, 2274-2274.	1.4	0
143	Quebec Platelet Disorder Is Associated With Greater Than Expected Increases In Urokinase Plasminogen Activator In Granulocytes and Monocytes. Blood, 2013, 122, 3573-3573.	1.4	0